<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02823236</url>
  </required_header>
  <id_info>
    <org_study_id>90/15</org_study_id>
    <nct_id>NCT02823236</nct_id>
  </id_info>
  <brief_title>Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars</brief_title>
  <acronym>LADISLAO</acronym>
  <official_title>Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars: 3-arm Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Dermatológico Dr. Ladislao de la Pascua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grupo Medifarma, S. A. de C. V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Dermatológico Dr. Ladislao de la Pascua</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy and safety of the combination of intralesional
      triamcinolone (at doses of 4mg / cm2 at intervals of 4 weeks) and topical pirfenidone 8%
      (every 8 hours continuously) compared with their isolated application, in the treatment of
      keloid scars in adults. The duration of this three-arm clinical trial will be 12 months, a
      6-month period for treatment and a follow-up of 6 months to assess recurrences. The estimated
      number of persons to be recruited and randomized for the study is 102.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with keloid scars will be randomized to 3 arms of treatment in order to assess
      the efficacy of combining intralesional triamcinolone and topical pirfenidone compared with
      the isolated application of these drugs. The interventions will last 6 months but the
      individuals will be assessed monthly to determine recurrences for 6 more months. The scar
      size will be measure at weeks 12, 24 and 52.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2016</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Keloid Scar Assessment</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Assessment using the Vancouver Scar Scale (VSS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Keloid Scar Assessment by Patients</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Assessment using the Patient and Observer Scar Assessment Scale (POSAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse effects</measure>
    <time_frame>Every 4 weeks after the beginning of the intervention up to 52 weeks</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the patient</measure>
    <time_frame>24 weeks</time_frame>
    <description>Dermatology Life Quality Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence defined as an increase size of the keloid scar at week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number of patients with an increase size of the keloid scar compared with the size obtained at week 24</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Keloid</condition>
  <arm_group>
    <arm_group_label>Intralesional Triamcinolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage commensurate with scar surface to be treated. After washing and drying the affected area, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone + Pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months. Simultaneously, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Pirfenidone</intervention_name>
    <description>Pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.</description>
    <arm_group_label>Topical Pirfenidone</arm_group_label>
    <other_name>KitosCell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone + Pirfenidone</intervention_name>
    <description>Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months. And pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.</description>
    <arm_group_label>Triamcinolone + Pirfenidone</arm_group_label>
    <other_name>Kenalog + KitosCell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralesional Triamcinolone</intervention_name>
    <description>Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months.</description>
    <arm_group_label>Intralesional Triamcinolone</arm_group_label>
    <other_name>Kenalog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Keloids size equal or major than 1 cm

          -  Keloids less than 5 years old

          -  Keloids in trunk

        Exclusion Criteria:

          -  Keloid with a surgical indication

          -  Hypertrophic scars

          -  Scars after burn wounds

          -  Pregnancy

          -  Lactation

          -  Use of systemic chemotherapeutics or chronic use of systemic corticosteroids or
             immunosuppressive medication

          -  Known hypersensitivity for triamcinolone or pirfenidone

          -  Severe comorbidity not controlled

          -  Inflammatory acne

          -  Diabetes Mellitus

          -  Hypertension

          -  Renal, hepatic or respiratory failure

          -  Topical treatment 4 weeks before recruitment

          -  Previous treatment with intralesional steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha Alejandra Morales-Sánchez, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Dermatológico Dr. Ladislao de la Pascua</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martha Alejandra Morales-Sánchez, MD, MSc</last_name>
    <phone>55387033</phone>
    <phone_ext>312</phone_ext>
    <email>mmoraless@sersalud.df.gob.mx</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Dermatológico &quot;Dr. Ladislao de la Pascua&quot;</name>
      <address>
        <city>Mexico City</city>
        <zip>06780</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Alejandra Morales-Sánchez, MD, MSc.</last_name>
      <phone>55387033</phone>
      <phone_ext>312</phone_ext>
      <email>mmoraless@sersalud.df.gob.mx</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keloid</keyword>
  <keyword>Scar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Pirfenidone</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

